Imatinib Impurities

veeprho banner
Parent Drug Name Name of Impurity Catalogue No.
Imatinib Imatinib Carboxylic Impurity VE009042View CAS 106261-49-8
Imatinib Imatinib EP Impurity A VL272007View CAS 55314-16-4
Imatinib Imatinib EP Impurity B VL272003View CAS 581076-65-5
Imatinib Imatinib EP Impurity B(HCl Salt) VE008330View CAS 581076-67-7
Imatinib Imatinib EP Impurity C (HCl Salt) VE008632View CAS 1820893-54-6
Imatinib Imatinib EP Impurity D VL272002View CAS 1821122-73-9
Imatinib Imatinib EP Impurity F VL272008View CAS 152460-10-1
Imatinib Imatinib EP Impurity H VL272005View CAS 350-03-08
Imatinib Imatinib EP impurity C VL272004View CAS 404844-02-6
Imatinib Imatinib Impurity 3 VL272006View CAS 152459-96-6
Imatinib Imatinib Impurity J VL272009View CAS 571186-91-9
Imatinib Imatinib N-Acetyl Impurity VE009742View CAS 1321600-78-5
Imatinib Imatinib Piperazine-N, N-DiOxide VE006650View CAS 571186-93-1
Imatinib Imatinib pyridine N oxide Impurity VL272010View CAS 571186-92-0
Dacarbazine | Imatinib | Metformin Metformin EP Impurity F VL101006View CAS 506-59-2

Request a quote

106261-49-8: Imatinib Carboxylic Impurity

106261-49-8: Imatinib Carboxylic Impurity
Catalogue No.

VE009042

CAS No.

106261-49-8

Molecular Formula

C13H20Cl2N2O2

Molecular Weight

307.22 g/mol

Parent drug

Imatinib

IUPAC Name

4-((4-Methylpiperazin-1-yl)methyl)benzoic acid dihydrochloride

Synonyms

N/A

References

Iqbal, Nida, and Naveed Iqbal. “Imatinib: A Breakthrough of Targeted Therapy in Cancer.” Chemotherapy Research and Practice, vol. 2014, May 2014, pp. 1–9, https://doi.org/10.1155/2014/357027. ‌

Status

In-stock

ListName

Imatinib Carboxylic Impurity

Exclusively Supplied by Veeprho

Exclusively Supplied by Veeprho

"*" indicates required fields

Hidden
Products quotation
Name
Url